Master of Science / Department of Anatomy and Physiology / Mark L. Weiss / Wharton's jelly is a non-controversial source of mesenchymal stromal cells. Isolation of the cells is non-invasive and painless. The cells have been shown to have a wide array of therapeutic applications. They have improved symptoms when transplanted in a variety of animal disease models, can be used in tissue engineering applications to grow living tissue ex vivo for transplantation, and can be used as drug delivery vehicles in cancer therapy. The cells have also been shown to be non-immunogenic and immune suppressive. This thesis focuses on optimizing isolation protocols, culture protocols, cryopreservation, and characterization of cells in different growth conditions. Results from the experiments indicate that isolation of cells by enzyme digestion yields cells consistently, a freezing mixture containing 90% FBS and 10% DMSO confers maximum viability, and the expression of mesenchymal stromal cell consensus markers does not change with passage and cryopreservation. The results of the experiments also show that cells grow at a higher rate in 5% oxygen culture conditions compared to 21% oxygen culture conditions, serum does not have an effect on growth of the cells, serum and oxygen do not have effects on the expression of mesenchymal stromal cell consensus markers and the cells are stable without nuclear abnormalities when grown in 5% oxygen and serum free conditions for six passages after first establishing in serum conditions.

No description available.

This present thesis comprise two major parts both experimental and numerical study which have been conducted in four distinct steps as following: (1) Design, construction, and evaluation of control and hydrodynamic of a bioreactor system. (2) Visualization of fluid flow perfusion in the hollow fibre membrane bioreactor (HFMB) using a biomedical noninvasive imaging technique, i.e. positron emission tomography (PET). (3) Development of a mathematical model for analyzing a hybrid hollow fibre membrane bioreactor (hHFMB) and (4) Development of a dynamic and two-porous media model for analyzing the HFMB with the aid of computational fluid dynamics (CFD), specifically for bone tissue engineering application. The experimental part includes the steps 1 and 2. In the step 1, the flow perfusion bioreactor system has been designed and constructed. The experimental evaluations of hydrodynamic, and control were performed. In this system, mean pressure, mean flow rate, frequency and waveform of the pulsatile pressure and flow rate can be modulated and controlled over the time to simulate both physiological and non-physiological conditions. The temperature, dissolved oxygen, and pH can be controlled.This bioreactor system can be applied to a variety of scaffold configurations, geometries, and sizes as the cell/tissue culture chamber is adjustable in length.This system is autoclavable, and compatible with noninvasive medical imaging techniques. Designing of the inlet and outlet manifold of the bioreactor were performed according to data obtained from CFD simulation of the flow distribution to achieve high efficiencies in the uniformity of flow perfusion. In the second step, PET was proposed for the very first time and a small animal PET system was used to obtain new information about steady and pulsatile flow patterns in the HFMB for tissue engineering applications. The non-homogeneous tracer distribution, as found with PET imaging, implies the occurrence of non-efficient regions with respect to mass transfer. In steady inlet flow condition, a non-uniform distribution of radioactive tracer was obtained. In contrast, the pulsatile inlet flow generated more uniform perfusion than that of steady flow. Further, it was found that in the case of pulsatile flow, the accumulation of the tracer within the bioreactor was efficiently less than that of steady inlet flow at the same condition. Therefore, in one hand these findings have the potential to improve bioreactor design and in the other hand can explore a very important rout to employ PET in developing bioreactors for tissue engineering applications. The numerical part includes the step 3 and 4 in which the numerical study has been performed for 3-D bone tissue growth in HFMB as a case study for large-scale tissue culture. In the step 3, the feasibility of utilizing newly proposed hHFMB for the growth of mesenchymal stem cells (MSCs) to form bone tissue was investigated using numerical simulations. To this aim, a mathematical model using a CFD code was developed to optimize the design and operation parameters of hHFMB for the growth of MSCs. The volume averaging method was used to formulate mass balance for the nutrients and the cells in the porous extracapillary space (ECS) of the hHFMB. The cell-scaffold construct in the ECS of the hollow fibres and membrane wall were treated as porous medium. Cell volume fraction dependent porosity, permeability, and diffusivity of mass were used in the model. The simulations allowed the simultaneous prediction of nutrient distribution and nutrient-dependent cell volume fraction. In addition, this model was used to study the effects of the operating and design parameters on the nutrient distribution and cell growth within the bioreactor. The modeling results demonstrated that the fluid dynamics within the ECS and transport properties and uptake rates in hHFMB were sufficient to support MSCs required for clinical-scale bone tissue growth in vitro and enabled to solve nutrition difficulties because of high cell density and scaffold size. In the step 4, the new dynamic and two-porous media model has been used for analyzing the nutrient-dependent MSCs growth in order to form the bone tissue in the HFMB. In the present model, hollow fibre scaffold within the bioreactor was treated as a porous domain. The domain consists of the porous lumen region available for fluid flow and the porous ECS region, filled with collagen gel containing cells, for growing tissue mass. Furthermore, the contributions of several design and process parameters, which enhance the performance of the bioreactor, were studied. In addition, the dynamic evaluation of cell growth, oxygen and glucose distributions were quantitatively analyzed. The obtained information can be used for better designing of the bioreactor, determining of suitable operational conditions and scale up of the bioreactor for engineering of clinical-scale bone tissue.--Résumé abrégé par UMI.

Background: The beneficial impact of mesenchymal stem cells (MSC) on both acute and chronic liver diseases has been confirmed, although the molecular mechanisms behind it remain elusive. We aim to identify factors secreted by undifferentiated and hepatocytic differentiated MSC in vitro in order to delineate liver repair pathways potentially targeted by MSC. Methods: Secreted factors were determined by protein arrays and related pathways identified by biomathematical analyses. Results: MSC from adipose tissue and bone marrow expressed a similar pattern of surface markers. After hepatocytic differentiation, CD54 (intercellular adhesion molecule 1, ICAM-1) increased and CD166 (activated leukocyte cell adhesion molecule, ALCAM) decreased. MSC secreted different factors before and after differentiation. These comprised cytokines involved in innate immunity and growth factors regulating liver regeneration. Pathway analysis revealed cytokine-cytokine receptor interactions, chemokine signalling pathways, the complement and coagulation cascades as well as the Januskinase-signal transducers and activators of transcription (JAK-STAT) and nucleotide-binding oligomerization domain-like receptor (NOD-like receptor) signalling pathways as relevant networks. Relationships to transforming growth factor beta(TGF-beta) and hypoxia-inducible factor 1-alpha (HIF1-alpha) signalling seemed also relevant. Conclusion: MSC secreted proteins, which differed depending on cell source and degree of differentiation. The factors might address inflammatory and growth factor pathways as well as chemo-attraction and innate immunity. Since these are prone to dysregulation in most liver diseases, MSC release hepatotropic factors, potentially supporting liver regeneration.

A traumatic skeletal muscle injury that involves the loss of a substantial portion of tissue will not regenerate on its own. Little is understood about the ability of the muscle to recover function after such a defect injury, and few research models exist to further elucidate the repair and regeneration processes of defected skeletal muscle. In the current research, a model of muscle injury was developed in the lateral gastrocnemius (LGAS) of the rat. In this model, the muscle gradually remodels but functional recovery does not occur over 42 days. Repair of the defect with muscle-derived extracellular matrix (ECM), improves the morphology of the LGAS. Blood vessels and myofibers grow into the ECM implant in vivo, but functional recovery does not occur. Addition of bone marrow-derived mesenchymal stem cells (MSCs) to the implanted ECM in the LGAS increases the number of blood vessels and regenerating myofibers within the ECM. Following 42 days of recovery, the cell-seeded ECM implanted LGAS produces significantly higher isometric force than the non-repaired and non-cell seeded ECM muscles. These results suggest that the LGAS muscle defect is a suitable model for the study of traumatic skeletal muscle injury with tissue loss. Additionally, MSCs seeded on an implanted ECM lead to functional restoration of the defected LGAS. / text

Les tendinites sont des lésions communes chez le cheval athlète, ayant un impact financier et sportif considérable. Les cellules souches mésenchymateuses (CSMs) de moelle osseuse (MO) sont empiriquement utilisées en clinique pour améliorer la guérison des affections myoarthrosquelettiques. Cependant, il est nécessaire de standardiser les protocoles d’isolement des CSMs équines et d’analyser leurs effets sur la guérison tendineuse pour ajuster leur dose. Les objectifs de cette étude étaient de comparer 3 méthodes d’isolement des CSMs équines et d’établir un modèle de guérison tendineuse minimal invasif pour analyser l’effet des CSMs sur cette guérison. Des CSMs de MO du sternum de juments étaient isolées par 3 protocoles couramment utilisés (adhérence au pétri (Classique) et 2 méthodes par gradient de densité (Percoll et Ficoll)). La viabilité des cellules après isolement, le rendement d’isolement, le nombre de CSMs obtenues après 14 jours de culture et leurs caractéristiques fonctionnelles (renouvellement et différentiation) étaient comparés entre les 3 protocoles. Les résultats suggéraient que le Percoll était le meilleur protocole en termes de rendement et de capacité de renouvellement des cellules. La différence n’était pas significative pour leur viabilité et leur capacité de différentiation. Un modèle de guérison tendineuse, consistant en une ténectomie du tendon extenseur latéral du doigt fut ensuite développé. Cependant, la grande variabilité interindividuelle de qualité de guérison dans le groupe pilote implique une ré-évaluation du modèle. Des études futures, avec des CSMs isolées par le Percoll dans de nouveaux modèles de guérison tendineuse devraient permettre de déterminer la dose adéquate de CSMs. / In equine athletes, tendinitis lesions are common and lead to substantial financial losses. Bone marrow (BM) mesenchymal stem cells (MSCs) are employed clinically empirically to enhance healing of musculoskeletal injuries. However, there is a need to standardize equine MSC isolation protocols, to analyze the effects of MSCs on tendon healing and to optimize dosage. The objectives of the study were to compare 3 methods of equine MSC isolation and develop a minimally invasive model of tendon healing to analyze the effects of MSCs on tendon healing. BM MSCs from the sternum of mares were isolated by 3 protocols (adherence to a plastic culture dish (Classic) and two gradient density separation protocols (Percoll and Ficoll)) to compare for cell viability, MSC yield, number of MSCs attained after 14 days of culture and functional characteristics (self-renewal and multilineage differentiation) of the MSCs. The results suggested that the Percoll protocol was the best of those assessed in terms of MSC yield and self-renewal potential and that MSCs retrieved with the Ficoll protocol had the lowest self-renewal. There were no significant differences in terms of cell viability and differentiation capacity. A tendon healing model was then developed and consisted of a 0.5 cm tenectomy of the lateral digital extensor tendon. However, interanimal variation of healing quality was so high within the pilot group that the model should be re-evaluated. Further studies using MSCs isolated with Percoll in other novel models of tendon healing would allow determination of the adequate dosage of MSCs.

L’apoptose endothéliale initie le processus menant au remodelage vasculaire et au développement de la néointima dans la vasculopathie du greffon. La formation de néointima résulte de l’accumulation de leucocytes, de matrice extracellulaire et de cellules positives pour l’actine musculaire lisse alpha (αSMA+) dans l’intima des artères, artérioles et capillaires du greffon. Les cellules αSMA+ dans la néointima sont des cellules musculaires lisses vasculaires (CMLV) dérivées du donneur ainsi que des cellules souches dérivées du receveur, dont des cellules souches mésenchymateuses (CSM). L’acquisition d’un phénotype anti-apoptotique chez ces cellules est déterminante pour le développement de la néointima. Le laboratoire de Dre Hébert a démontré que les cellules endothéliales (CE) apoptotiques libèrent des médiateurs induisant une résistance à l’apoptose chez les CMLV et les fibroblastes. Notamment, les CE apoptotiques relâchent la cathepsine L qui clive le perlécan et ainsi libère un fragment C-terminal correspondant au troisième motif laminine G du domaine V du perlécan (LG3). Le LG3 est anti-apoptotique pour les fibroblastes. Nous avons donc émis l’hypothèse que le LG3 est un des médiateurs clés libéré par les CE apoptotiques favorisant le développement de la néointima via l’induction d’un phénotype anti-apoptotique chez les cellules néointimales αSMA+. Nous avons démontré que les médiateurs libérés par les CE apoptotiques induisent un phénotype anti-apoptotique chez les CSM dépendant de l’activation de la voie ERK1/2. De plus, le LG3 active la voie ERK1/2 via son interaction avec les intégrines beta 1 et induit une réponse anti-apoptotique chez ces cellules. Cependant l’activation de ERK1/2 par le LG3 est plus faible en comparaison de son activation par le milieu conditionné par des CE apoptotiques. Nos résultats suggèrent que les CE apoptotiques libèrent aussi de l’EGF qui agit de façon paracrine sur les CSM en coopération avec le LG3 pour induire un phénotype anti-apoptotique chez les CSM. Nous avons poursuivi l’étude de l’effet du LG3 in vivo sur le remodelage vasculaire en transplantation. Nous avons pour cela développé un modèle murin de rejet vasculaire qui consiste en une transplantation aortique entre des souris alloincompatibles. Nous avons ensuite injecté du LG3 chez les souris receveuses en post-transplantation. Nous avons observé dans ce modèle que des niveaux augmentés de LG3 sérique augmentent la formation de néointima, favorisent l’accumulation de cellules néointimales αSMA+ et diminuent le nombre de cellules CD31+ au niveau du greffon aortique. Parallèlement nous avons vérifié que le LG3 induit aussi un phénotype anti-apoptotique chez les CMLV et nous avons démontré un nouvel effet du LG3, soit une activité pro-migratoire, qui dépend de l’activation de la voie ERK1/2 chez les CMLV. Nous avons complété cette étude par l’analyse des niveaux de LG3 sérique dans une cohorte de patients receveurs d’allogreffe rénale. Nous avons observé chez ces patients, une association entre des niveaux élevés de LG3 sérique et un rejet vasculaire. Le LG3 contribue à la formation de néointima par son activité pro-migratoire et pro-survie chez les cellules néointimales et aussi de par son activité angiostatique. Nos résultats suggèrent que le LG3 est un nouveau médiateur important dans le remodelage vasculaire en transplantation / In allogeneic transplanted organs, endothelial apoptosis is associated with vascular remodeling and neointima formation which in turn leads to allograft vasculopathy, a maladaptive form of vascular repair. In allograft vasculopathy, neointima results from the accumulation of leukocytes, extracellular matrix and alpha-smooth muscle actin positive (αSMA+) cells in the intima of allogeneic arteries, arterioles and capillaries. Neointimal αSMA+ cells comprise vascular smooth muscle cells (VSMC) derived from the donor and stem cells derived from the recipient, including mesenchymal stem cells (MSC). Acquisition of an anti-apoptotic phenotype of neointimal cells is central to the development of vascular obliterative changes. Dr Hébert’s team demonstrated that apoptotic endothelial cells release mediators which in turn induce a state of resistance to apoptosis of VMSC and fibroblasts. Apoptotic endothelial cells release cathepsin-L which cleaves perlecan therefore releasing a C-terminal fragment harbouring a laminin G motif and referred to as LG3. LG3 is anti-apoptotic for fibroblasts. We hypothesized that LG3 is a key mediator produced by endothelial apoptosis of importance in favoring neointima formation via the induction of an anti-apoptotic phenotype in αSMA+ neointimal cells We demonstrated that mediators released by endothelial apoptosis induce an ERK1/2-dependent anti-apoptotic phenotype in MSC. We identified LG3 as one of the mediators implicated in the induction of this anti-apoptotic response. Interactions between LG3 and beta 1 integrins expressed on MSC trigger ERK1/2 activation albeit to a lesser degree than medium conditioned by apoptotic endothelial cells. We showed that apoptotic endothelial cells also release EGF which cooperates with LG3 to induce an anti-apoptotic phenotype on MSC through cross-talk between EGF receptor and integrin-dependent pathways. Next, we characterized the impact of LG3 on allogeneic vascular remodeling in vivo. We developed a murine model of vascular rejection based on orthotopic transplantation of an aortic segment between two fully MHC-incompatible mice in absence of immunosuppression. Recombinant LG3 was injected intravenously post-transplantation in recipients resulting in higher circulating levels of LG3. In LG3-injected mice, accumulation of αSMA+ neointimal cells was enhanced resulting in significantly increased intima/media ratios in the allogeneic aortic graft. Aortic grafts of LG3-injected allografts also showed decreased CD31+ cells. We also demonstrated, using cell-based approaches, that LG3 exerts a pro-migratory activity on VSMC through beta 1-integrin and ERK1/2 -dependent pathways. In line with these observations we also reported augmented serum LG3 in human renal transplant patients in association with acute vascular rejection episodes. Collectively these results suggest that the pro-migratory, pro-survival and angiostatic activities of LG3 contribute to neointima formation. Our results suggest that LG3 is a novel mediator of importance in the development of obliterative vascular remodeling associated with rejection of allogeneic organs.

La vasculopathie du greffon est une pathologie caractérisée par un rétrécissement progressif et oblitérant des vaisseaux sanguins menant à une ischémie et une perte de fonction du greffon. Le rétrécissement vasculaire est dû à une accumulation de matrice extracellulaire (MEC) et de cellules mononuclées positives pour l’actine musculaire lisse alpha (alphaSMA) dont les cellules souches mésenchymateuses, le tout formant une néointima oblitérante. Cette pathologie est la cause principale de la perte des greffons rénaux et cardiaques à long terme. Le rejet vasculaire aigu est un prédicteur de la vasculopathie du greffon. L’équipe du Dr Hébert a démontré que l’apoptose endothéliale, qui joue un rôle important dans le développement du rejet vasculaire, initie la libération de LG3, un fragment du protéoglycan perlécan. Les taux sanguins et urinaires de LG3 sont augmentés chez les receveurs d’allogreffe rénale avec rejet vasculaire et vasculopathie du greffon. Les résultats obtenus en laboratoire durant ma maîtrise ont permis de mieux caractériser l’impact du LG3 sur un type cellulaire important participant à la formation de néointima : les cellules souches mésenchymateuses. Mes travaux ont démontré que le LG3 induit à la fois la migration horizontale des MSC et la transmigration des MSC. Cette migration est dépendante de la voie de signalisation d’ERK1/2, précédemment identifiée comme voie centrale dans la formation de néointima. De plus, nos résultats démontrent que la kinase Src est activée en amont de l’activation de la voie MAPK. La migration horizontale et la transmigration induites par le LG3 sont aussi dépendantes des intégrines alpha2beta1, ainsi que l’activation de la voie MAPK. Dans un modèle de transplantation murin, nous avons également démontré que l’injection sérique de LG3 recombinant favorise l’accumulation de cellules positives pour alphaSMA dans la néointima. En outre, lorsque le receveur est déficient pour l’intégrine alpha2, mais que le greffon est sauvage, la formation de néointima induite par l’injection de LG3 est diminuée dans le greffon suggérant que les cellules du receveur jouent un rôle important dans la formation de la néointima. Enfin, nous avons démontré que l’injection de LG3 augmente aussi le nombre de cellules positives pour la forme phosphorylée d’ERK1/2 (p-ERK1/2) dans la néointima du greffon et que cette accumulation est dépendante de la présence des intégrines 2 1 chez les cellules du receveur.Lorsque le receveur est sauvage, il y a une augmentation du nombre de cellules positives pour p-ERK1/2. L’investigation de ces mécanismes dans le remodelage vasculaire expose de nouvelles opportunités pour inhiber la réponse cellulaire qui mène au remodelage inadapté lors d’un dommage vasculaire chronique et ainsi prolonger la survie du greffon. / Graft vasculopathy is diseases characterized by a progressive and obliterate narrowing of the blood vessels leading to ischemia and loss of graft function. This vascular narrowing is due to an accumulation of extracellular matrix and mononuclear cells positive for alpha smooth muscle actin (alphaSMA) including mesenchymal stem cells, thus forming an occlusive neointima. This condition is the leading cause of long term loss of kidney and heart transplants. Acute vascular rejection is a predictor of graft vasculopathy. Dr. Hébert’s team has demonstrated that endothelial apoptosis, which plays an important role in the development of vascular rejection, initiates the release of LG3, a fragment of the proteoglycan perlecan. Blood and urine levels of LG3 are increased in renal allograft recipients with vascular rejection and graft vasculopathy. The results obtained in the laboratory during my Master have helped to better characterize the impact of LG3 on an important cell type involved in neointima formation: the mesenchymal stem cells. My work has shown that the LG3 induces both the horizontal migration and the transmigration of MSC. This migration is ERK1/2-dependent, previously identified as a key molecule involved in neointima formation. In addition, our results demonstrate that Src kinase is activated by upstream activation of the MAPK pathway. Horizontal migration and transmigration induced by LG3 are also dependent on alpha2beta1 integrins, and the activation of the MAPK pathway. In a murine transplantation model, we also demonstrated that intravenous injection of recombinant LG3 promotes the accumulation of alphaSMA positive cells in the neointima. In addition, when the recipient is deficient for the alpha2 integrin but the graft is wild type, LG3 fails to induce neointima formation in the graft suggesting that recipient cells play an important role in the neointima formation. Finally, we demonstrated that intravenous injection of LG3 also increases the number of positive cells for the phosphorylated form of ERK1/2 (p-ERK1/2) in the neointima. This accumulation is dependent on the presence of alpha2beta1 integrins on recipient cells: when the recipient is wild type, there is an increase in the number of cells positive for p-ERK1/2.The investigation of these mechanisms in vascular remodeling presents new opportunities to inhibit the cellular response that leads to inadequate remodeling during chronic vascular damage and prolong graft survival.

Mesenchymal stem cells (MSC) possess a multilineage differentiation potential and have the ability to regulate reactivity of the immune system. They are usually isolated and expanded from the bone marrow, adipose tissue or umbilical cord. MSC represent promising cell population for the treatment of some severe diseases, such as amyotrofic lateral sclerosis (ALS), due to the combination of regenerative and immunomodulatory properties. The aim of this study is to compare MSC from ALS patients and healthy donors in their phenotype, proliferative activity and mainly their immunomodulatory properties. The assessment of impact of the disease on the properties of MSC is important for their autologous use in clinical trials. In this study we used MSC isolated from bone marrow of 14 ALS patients and 15 patients undergoing mostly orthopedic surgery as control group. We also used MSC stimulated for 24 hours by poinflammatory cytokines. Cells were compared in terms of immunophenotype, differentiation in adipocytes and osteoblasts, metabolic activity, expression of selected genes for immunomodulatory molecules and for inhibition of lymphocyte proliferation. Further experiments were focused on evaluation of immunomodulatory properties of MSC. The effect of MSC on peripheral blood mononuclear cells stimulated...

Origin of mammalian somatic cells in the developing testes remains unclear. This origin could be explained by established cell culture derived from testes of Xenopus tropicalis juvenile male. The expression profile of the cell culture showed transcription of some pluripotency genes, somatic Sertoli and peritubular myoid cell markers and last but not least, the mesenchymal stem cell markers. Conversely, germ cell genes were downregulated. Immunocytochemical analysis revealed expression of Vimentin, Sox9 and α-smooth muscle actin, indicating that the testicular cell culture is a common mesenchymal progenitor of the Sertoli and peritubular myoid cells and that the cell culture did not arise from spermatogonial stem cells undergoing incomplete reprogramming in vitro. Testing of X. tropicalis cell culture during induction of differentiation in vitro revealed that these cells are probably multipotent with the ability to differentiate into adipocytes, chondroblasts and osteoblasts. The ability to derive multipotent stem cells from the juvenile testes opens new possibilities of using these cells for biotechnology and medicine. Keywords: Testicular somatic cells, Xenopus tropicalis, progenitor, mesenchymal stem cells, induction of differentiation, multipotency